• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Model uses AI to predict prognosis for patients newly diagnosed with multiple myeloma

by | Feb 15, 2024 | Uncategorized

Researchers at several institutions collaborated to develop the first computational model that predicts prognosis for patients newly diagnosed with multiple myeloma based on tumor genomics and treatments.The prediction model for individualized risk in newly diagnosed...

Obesity linked to higher rates of a common precursor to multiple myeloma

by | Feb 14, 2024 | Uncategorized

Monoclonal gammopathy of undetermined significance, a common precursor to multiple myeloma, developed significantly more in individuals with obesity, according to a study published in Blood Advances.Those who smoked heavily and those who slept less than 6 hours per...

Super Bowl Player Reflects on Cancer Diagnosis, Congressman Returns to Work After Myeloma Treatment and More

by | Feb 9, 2024 | Uncategorized

Source: CureToday articles From the San Francisco 49ers’ Trent Williams looking back on his cancer experience to a Republican congressman returning to work after myeloma treatment, here’s what’s happening in the oncology space this week. Read...

Blenrep Combo for Relapsed, Refractory Myeloma Improves Outcomes

by | Feb 9, 2024 | Uncategorized

Source: CureToday articles Patients with relapsed or refractory multiple myeloma had lower progressive disease outcomes when receiving Blenrep with Velcade and dexamethasone, research found. Read More

Early-phase CAR-T for multiple myeloma shows ‘amazing’ safety, ‘encouraging’ efficacy

by | Jan 16, 2024 | Uncategorized

Results of a phase 1 trial for chimeric antigen receptor T cells targeting an orphan receptor in patients with relapsed or refractory multiple myeloma “thrilled” researchers, based on data presented at ASH Annual Meeting and Exhibition.Recipients of the autologous CAR...

VIDEO: Preliminary IsKia trial results promising in multiple myeloma subgroup

by | Jan 5, 2024 | Uncategorized

Healio spoke with Chakra Chaulagain, MD, about preliminary phase 3 results from the IsKia trial presented at ASH Annual Meeting and Exposition.The trial assessed the safety and efficacy of isatuximab (Sarclisa, Sanofi)-carfilzomib-lenalidomide-dexamethasone (IsaKRd)...
« Older Entries
Next Entries »

Recent Content

  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT